BRCA1 and ovarian carcinoma: We found NIH-OVCAR3 cells were 5-fold more sensitive to carboplatin than the 12 ovarian cancer cell lines (Figure 2B,D), which was comparable to the ovarian cancer cells with homozygous mutations in BRCA1.